Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology…

By S. Rajkumar, E. Blood, D. Vesole, R. Fonseca, P. Greipp. Journal of Clinical Oncology, 2006

870 citations recorded by the source corpus.

Subfields: Hematology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/e911518c14dffe2ce9d25a5bdd8d0bf20df1069f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. Huanhuan Chen
2. Li-li Zheng
3. Zhenling Liu
4. Li-Ping Sun
5. Lei Shi

Citations in the corpus

• Angiogenic signaling pathways and anti-angiogenic therapy for cancer (2023, background): “And it was not until 2006 that thalidomide received approval from FDA for multiple myeloma (MM) based on a phase III clinical trial combined with dexamethasone.(401) Another unexpected harvest is that thalidomide sensitizes icotinib to increase apoptosis and prevent migration in humanized NSCLC cell”